Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Subscribe To Our Newsletter & Stay Updated
